Abdallah, Nadine http://orcid.org/0000-0001-9195-1589
Rajkumar, S. Vincent http://orcid.org/0000-0002-5862-1833
Greipp, Patricia
Kapoor, Prashant
Gertz, Morie A. http://orcid.org/0000-0002-3853-5196
Dispenzieri, Angela http://orcid.org/0000-0001-8780-9512
Baughn, Linda B.
Lacy, Martha Q.
Hayman, Suzanne R.
Buadi, Francis K.
Dingli, David
Go, Ronald S. http://orcid.org/0000-0002-8284-3495
Hwa, Yi L.
Fonder, Amie
Hobbs, Miriam
Lin, Yi
Leung, Nelson http://orcid.org/0000-0002-5651-1411
Kourelis, Taxiarchis
Warsame, Rahma
Siddiqui, Mustaqeem http://orcid.org/0000-0002-4640-7311
Lust, John
Kyle, Robert A.
Bergsagel, Leif http://orcid.org/0000-0003-1523-7388
Ketterling, Rhett
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Article History
Received: 27 June 2020
Revised: 29 July 2020
Accepted: 30 July 2020
First Online: 11 August 2020
Conflict of interest
: P.K. received research funding from Takeda Pharmaceuticals, Celgene, and Amgen. M.A.G. served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. A.D. received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen and received a travel grant from Pfizer. M.Q.L. received research funding from Celgene. D.D serves as a consultant for Alexion, Apellis, Glaxo Smith Kline, Janssen, Millenium/Takeda, Rigel, and received research funding from Juno Therapeutics and Karyopharm Therapeutics. N.L. serves on an advisory board for Takeda Pharmaceuticals. S.K.K. served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol-Myers Squibb and received research funding from Celgene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol-Myers Squibb. The remaining authors declare that they have no conflict of interest.